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Abbreviations
ACS Acute coronary syndrome
AHRQ                                              Agency for Healthcare Research and Quality
ALL Acute Lymphoid Leukemia
AMI Acute Myocardial Infarction
AML Acute Myeloid Leukemia
CABG Coronary Artery Bypass Grafting
CLL Chronic Lymphoid Leukemia
CML Chronic Myeloid Leukemia
CVA Cerebrovascular Accident
MACCE Major Adverse Cardiovascular and Cerebrovascular 
Event 
NSTEMI Non –ST-elevation myocardial infarction
OR Odds Ratio
PCI Percutaneous Coronary Intervention
STEMI ST-elevation myocardial infarction
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Abstract
Background: Patients with leukemia are at increased risk of cardiovascular events. There are 
limited outcomes data for patients with a history of leukemia who present with an acute 
myocardial infarction (AMI). 
Methods:  We queried the Nationwide Inpatient Sample (2004-2014) for patients with a 
primary discharge diagnosis of AMI, and a concomitant diagnosis of leukemia, and further 
stratified according to the subtype of leukemia. Multivariable logistic regression was conducted 
to identify the association between leukemia and major acute cardiovascular and 
cerebrovascular events (MACCE; composite of mortality, stroke and cardiac complications) 
and bleeding.
Results: Out of 6,750,878 AMI admissions, a total of 21,694 patients had a leukemia diagnosis. 
The leukemia group experienced higher rates of MACCE (11.8% vs. 7.8%), mortality (10.3% 
vs. 5.8%) and bleeding (5.6% vs. 5.3%). Following adjustments, leukemia was independently 
associated with increased odds of MACCE (OR 1.26[1.20,1.31]) and mortality (OR 
1.43[1.37,1.50]) without an increased risk of bleeding (OR 0.86[0.81,0.92]). Acute myeloid 
leukemia (AML) was associated with approximately three-fold risk of MACCE (OR 2.81[2.51, 
3.13]) and a four-fold risk of mortality (OR 3.75[3.34, 4.22]). Patients with leukemia were less 
likely to undergo coronary angiography (CA) (48.5% vs. 64.5%) and percutaneous coronary 
intervention (PCI) (28.2% vs. 42.9%) compared to those without leukemia.
Conclusion: Patients with leukemia, especially those with AML, are associated with poor 
clinical outcomes after AMI, and are less likely to receive CA and PCI compared to those 
without leukemia. A multi-disciplinary approach between cardiologists and hematology 
oncologists may improve the outcomes of patients with leukemia after AMI.
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What is known about this topic? 
•Little is known about the prevalence of leukemia amongst patients presenting with 
AMI.
•There are inconsistencies in current evidence on outcomes and management strategies 
of AMI in patients with leukemia.
What does this article add? 
•We report the prevalence of patients with leukemia presenting with acute myocardial 
infarction from a nationwide analysis for the first time in literature.
•A diagnosis of leukemia, especially the acute myeloid type, is independently associated 
with worse clinical outcomes in the context of AMI.
•Patients with leukemia are less likely to be offered invasive coronary imaging and 
intervention after acute myocardial infarction (AMI).
•The study emphasizes the need for a multidisciplinary approach to the management of 
patients with leukemia, involving both hemoncologists and cardiologists.
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Introduction
As of 2018, leukemia is the tenth most common type of cancer in the United States, 
with a reported incidence of 13.8 per 100,000 with an average rise of 0.3% in new cases per 
year over the last decade.1 It is estimated that 1 in 64 men and 1 in 94 women will be diagnosed 
with leukemia during their lifetime.2 The survival of leukemia patients has improved in recent 
years due to improvement in both diagnostic and therapeutic modalities. However, this 
improvement in life expectancy has led to an increase in the burden of cardiovascular disease 
in these patients. 
Leukemias are classified on the basis of cellular phenotype and degree of differentiation 
on initial presentation, with the most common subtypes being acute lymphoblastic (ALL), 
acute myeloid (AML), chronic lymphocytic (CLL), and chronic myeloid (CML) leukemias. 
Each subtype of leukemia is different in terms of clinical course and outcomes, particularly in 
relation to risk of thrombotic and major bleeding complications. The pathogenesis of vascular 
complications in leukemia is complex and multifactorial. The pathophysiologic mechanisms 
include leukostasis, anemia, depletion of circulating anticoagulants, and the use of 
chemotherapeutic agents.3 Despite the fact that the majority of vascular thrombotic phenomena 
affect the pulmonary and central nervous systems, acute myocardial infarction is well 
recognized in leukemia patients.3-5
To date, there is no literature on the prevalence of leukemia amongst patients presenting 
with acute myocardial infarction (AMI). Furthermore, there is little data on the outcomes of 
these patients, given the exclusion of patients with active malignancy in cardiovascular 
randomized trials.6 The current literature is limited to isolated case reports and reviews, 4,5,7-
9 without a detailed study on the clinical characteristics, treatments and outcomes of AMI in 
leukemia patients including among different leukemia subtypes. 
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The current study utilized a large contemporary cohort drawn from the National 
Inpatient Sample from 2004 to 2014 to evaluate the association between a leukemia diagnosis 
and clinical outcomes of AMI. The study was designed to examine the clinical characteristics, 
processes of care, economic burden and in-hospital outcomes stratified by both the presence of 
leukemia and leukemia subtype.
Methods 
Data Source
The National Inpatient Sample (NIS), is the largest publicly available all-payer database 
of hospitalized patients in the United States and is sponsored by the Agency for Healthcare 
Research and Quality (AHRQ) as a part of the Healthcare Cost and Utilization Project.10 It 
includes anonymized data on primary and secondary discharge diagnoses and procedures from 
more than 7 million hospitalizations annually. The NIS dataset was designed to approximate 
20% stratified sample of United States community hospitals and provides sampling weights to 
calculate national estimates that represent more than 95% of the US population. The estimates 
of hospital characteristics, numbers of discharges, length of stay, and in-hospital mortality from 
the HCUP Nationwide Inpatient Sample (NIS) for 2007 were highly comparable to three 
related data sources: the American Hospital Association (AHA) Annual Survey Database, the 
National Hospital Discharge Survey (NHDS) from the National Center for Health Statistics, 
and the MedPAR inpatient data from the Centers for Medicare and Medicaid Services 
(CMS).11 Furthermore, NIS was found to have a more comprehensive demographic capture 
when compared to a large multistate EHR dataset in more than 25 diagnosis groups, including 
cardiovascular disorders.12
Study Design and Population
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A retrospective observational analysis using the NIS database from 2004 to 2014 was 
performed. A total of 1,367,844 records with a primary discharge diagnosis of AMI, including 
ST-Elevation myocardial infarction (STEMI) and non-ST elevation myocardial infarction 
(NSTEMI), were extracted from the NIS datasets using the International Classification of 
Diseases, 9th Revision, Clinical Modification (ICD-9) codes, corresponding to a total of 
6,750,878 discharge estimates after applying the discharge weight. ICD-9 and Clinical 
Classification Software (CCS) codes used to identify patient characteristics, outcomes and 
comorbidities are listed in Supplementary Table 1. The cohort was stratified according to the 
presence or absence of leukemia, which was also identified using the relevant ICD-9 codes, 
into 2 groups, namely ‘no leukemia’ and ‘leukemia’. The leukemia group was further stratified 
according to diagnosis into 4 subgroups (AML, CML, ALL and CLL) for sub-analysis 
purposes. All patients who were ≥18 years of age were included. Records with missing age, 
gender, admission or discharge date, length of stay and mortality were excluded from the 
analysis. A flow diagram illustrating the selection process in the present study is presented in 
Supplementary Figure 1. 
Procedural data and clinical outcomes other than in-hospital mortality, length of stay 
and total charges were extracted using the relevant ICD-9  and CCS diagnosis and procedure 
codes listed in Supplementary Table 1; bleeding, cardiac complications, use of assist device or 
intra-aortic balloon pump (IABP), shock during hospitalization and the receipt of coronary 
angiography and revascularization (PCI and CABG). 
Outcomes
The co-primary outcomes were in-hospital rates of major acute cardiovascular and 
cerebrovascular events (MACCE), all-cause mortality, acute stroke/TIA and all-cause 
bleeding. MACCE was defined as a composite of all-cause mortality, stroke and cardiac 
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complications (pericardiocentesis, cardiac tamponade, hemopericardium or coronary 
dissection). Bleeding was defined as any post-procedural hemorrhage or haematomas, or 
bleeding requiring transfusion according to ICD-9 and CCS codes specified in Supplementary 
Table 1. 
The secondary outcome was to evaluate differences in receipt of invasive management, 
including coronary angiography and revascularization (PCI or CABG), and economic burden 
of a concomitant leukemia diagnosis in patients hospitalized for AMI as measured by length 
of stay and total hospitalization charges.
Statistical Analysis
Statistical analysis was performed using SPSS version 24 (IBM Corp, Armonk, NY). 
Continuous variables are presented as medians with interquartile range (IQR) and were 
compared using the Mann-Whitney test for differences between leukemia and non-leukemia 
groups and using the Kruskal-Wallis test for difference between leukemia subgroups.  
Categorical variables are presented as percentages and were analyzed using the chi-squared 
(X2) test. 
Multivariable logistic regression was used to assess 1) the impact of any leukemia on 
in-hospital adverse outcomes and 2) differences in adverse outcomes between leukemia 
subgroups in comparison to patients without leukemia. The following covariates were adjusted 
for in all analyses: age, sex, elective admission, weekend admission, primary expected payer, 
median household income, dyslipidemia, smoking status, previous AMI, previous coronary 
artery bypass grafting (CABG), history of ischemic heart disease (IHD), previous percutaneous 
coronary intervention (PCI), previous cerebrovascular accident (CVA), thrombocytopenia and 
family history of coronary artery disease (CAD), use of assist device or intra-aortic balloon 
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pump (IABP), shock during hospitalization, receipt of coronary angiography or PCI during 
admission, bed size of hospital, region of hospital, location/teaching status of hospital, 
thrombocytopenia, and 29 AHRQ comorbidities (acquired immune deficiency syndrome, 
alcohol abuse, deficiency anemias, chronic blood loss anemia, rheumatoid arthritis/collagen 
vascular diseases, congestive heart failure, chronic pulmonary disease, coagulopathy, 
depression, uncomplicated diabetes, diabetes with chronic complications, drug abuse, 
hypertension, hypothyroidism, liver disease, lymphoma, fluid and electrolyte disorders, 
metastatic cancer, other neurological disorders, obesity, paralysis, peripheral vascular 
disorders, psychoses, pulmonary circulation disorders, renal failure, solid tumor without 
metastasis, peptic ulcer diseas  excluding bleeding, valvular heart disease, and weight loss). 
All odds ratios (ORs) are adjusted for the aforementioned covariates and presented with the 
corresponding 95% confidence intervals (CI) between square brackets. 
Results
A total of 6,968,777 hospitalizations for AMI were recorded in the United States 
between 2004 and 2014. After excluding all discharges with missing data on covariates or 
outcomes, as well as cases with more than one leukemia diagnosis, a total of 6,750,878 patients 
were included in the final analysis (Supplementary Figure 1). The total numbers of exclusions 
accounts for approximately 3% of the original dataset. 
The patient characteristics of the study population are presented according to the 
presence or absence of leukemia in Table 1. Patients with a current history of leukemia 
diagnosis comprised 0.3% (n=21,694) of the study cohort. AMI patients with a leukemia 
diagnosis were almost a decade older (77 vs. 68 years), more likely to be male (65.2% vs. 
60.2%) and of White ethnic background (87.8% vs. 77.1%). Furthermore, patients with 
leukemia were less likely to be diagnosed with STEMI during admission (24.8% vs. 35.1%) 
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and more likely to have abnormal hematological parameters including thrombocytopenia 
(14.0% vs. 3.1%), coagulopathy (17.4% vs. 4.2%) and deficiency anemias (25.4% vs. 14.6%). 
The leukemia group was further stratified according to diagnosis into four subgroups; 
AML (10.5%, n=2278), CML (15.8%, n=3437), ALL (1.7%, n=379) and CLL (71.9%, 
n=15,600), the latter being the most common subtype. Supplementary Table 2 shows the 
patient characteristics of each of the leukemia subgroups. Several key differences were seen 
across the leukemia groups. There was more than a decade difference in the median age range 
between groups (65-79 years) with ALL patients being predominantly younger (65 years) and 
CLL patients being older (79 years). The percentage of males ranged from 62.6% to 73.6% 
with a higher prevalence of m n in the acute leukemia groups than in the chronic leukemia 
groups (Males %: CML: 62.6% and CLL 64.4% vs. AML 72.8% and ALL 73.6%). The highest 
rate of thrombocytopenia was observed in the AML group (25.1%) Furthermore, ALL patients 
were less likely to be of ‘White’ ethnic background compared to all other subgroups (78%). 
Management strategy
Patients with leukemia were less likely to receive coronary angiography (48.5% vs. 
64.5%) or any revascularization (PCI: 28.2% vs. 42.9%; CABG: 6.9% vs. 8.9%) (Table 2, 
Figure 1). Within the leukemia subgroups, AML patients were the least likely to receive 
coronary angiography (33.4%), PCI (20.2%) or CABG (3.2%). (Table 3) 
In-hospital Mortality, MACCE and Stroke
Patients with leukemia experienced significantly higher rates of in-hospital MACCE 
(11.8% vs. 7.8%) and mortality (10.3% vs. 5.8%) in comparison to those without leukemia 
(Table 2, Figure 2). However, the rates of in-hospital stroke and cardiac complications were 
lower in patients with leukemia (stroke: 1.4% vs. 1.7%; cardiac complications: 0.5% vs. 0.7%, 
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respectively). Multivariable analysis was performed to determine the adjusted effect of 
leukemia on in-hospital outcomes (Tables 5). The presence of leukemia was associated with a 
25% increase in odds of MACCE (OR 1.26 [1.20, 1.31]) and 40% increase in odds of mortality 
(OR 1.43 [1.37, 1.50]). In contrast, the presence of leukemia was associated with lower odds 
of in-hospital stroke (OR 0.71 [0.64, 0.80]).
In subgroup analysis according to leukemia subtype, the highest rates of in-hospital 
MACCE and mortality were found in patients with AML (21.1% and 20.2% respectively), 
while the lowest rates of both events were found in ALL (MACCE: 8.5%; mortality: 7.3%) 
(Figure 2). Patients with CML had the highest rates of in-hospital stroke (2.0%) and cardiac 
complications (1.0%) in comparison to all other subgroups. 
In comparison to patients without leukemia, patients with AML were approximately at 
3-fold increased odds of MACCE (OR 2.81 [2.51, 3.13]) and 4-fold increased odds of mortality 
(OR 3.75 [3.34, 4.22]) (Supplementary Table 3, Figure 3). Patients with ALL were also at 
increased odds of mortality (OR 1.73 [1.14, 2.63]). The effect of lymphoid leukemias on 
MACCE was not found to be statistically significant (ALL: OR 1.32 [0.90, 1.94]; CLL: OR 
1.06 [0.99, 1.11]). Patients with AML and CLL were associated with significantly reduced 
odds of in-hospital stroke (OR 0.47 [0.30, 0.73] and OR 0.68 [0.59, 0.78], respectively) 
whereas no difference in stroke was found between ALL and CML groups (OR 0.78 [0.31, 
1.99] and OR 1.04 [0.81, 1.33], respectively) and those without leukemia. (Supplementary 
Table 3, Figure 3).
Bleeding
Patients with leukemia experienced higher rates of in-hospital bleeding compared to 
those without leukemia (5.6% vs. 5.3%; Table 2, Figure 2). However, in multivariate analysis 
the adjusted effect of leukemia was a reduction in odds of bleeding (OR 0.86 [0.81, 0.92]).  
Within the subgroups of leukemia, patients with CML had the highest rates of bleeding (7.2 
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%) while patients with AML experienced the lowest rates of bleeding (4.4%) (Table 3, Figure 
2). In comparison to patients without leukemia, patients with CML were at 20% increased odds 
of bleeding (adjusted OR 1.20 [1.05, 1.37]) while all other subgroups were associated with 
reduced odds of bleeding (Supplementary Table 3, Figure 3). 
Length of stay and hospitalization charges
The median length of hospital stay of leukemia patients was marginally longer than in 
patients without leukemia (4 vs. 3 days). However, there was no difference in length of stay 
between the leukemia subgroups (4 days in all subgroups, p=0.76) (Table 3). While the total 
charge of hospitalization was less in patients with leukemia (median total charges: $39,387 vs. 
$43,155, Table 2), there was a notable variation in median costs between leukemia subgroups. 
Patients with ALL represented the most expensive median cost of hospitalization amongst 
subgroups ($47,674), followed by CML ($42,302), CLL ($39,387) and AML ($36,516) (Table 
3).
Discussion
Our analysis of a national cohort of over 21,000 patients with leukemia presenting with 
an AMI suggests that patients with leukemia are older, have more comorbidities and are less 
likely to receive either diagnostic cardiac catheterization or coronary revascularization 
compared to patients without leukemia. We also observe that patients with leukemia are a 
heterogenous group of patients with different risk factor profiles and clinical outcomes 
following presentation with AMI, with the chronic forms of leukemia (CLL and CML) being 
most commonly encountered and accounting for 85% of cases. Finally, we show, that whilst 
all leukemia is associated with a poorer prognosis, patients with AML have the poorest 
prognosis, with a 4-fold and 3-fold increased odds mortality and MACCE, respectively, whilst 
patients with CML are at the highest risk of major bleeding complications. 
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With active malignancy being an exclusion criterion in most AMI trials, clinicians are 
faced with a lack of data to guide their decision-making. Given the numerous unknowns in the 
platelet and coagulation cascade of these patients with hematologic malignancies, there may 
be hesitation to simply extrapolate standard AMI treatment protocols in these patients. Use of 
anticoagulants, antiplatelets, and invasive strategies for AMI carries the obvious risk of 
bleeding complications but whether that risk outweighs the benefit in leukemia patients is 
unknown, nor is it known if certain subtypes of leukemia respond differently. This study helps 
to understand the differences in AMI management, outcomes, and complications in patients 
with leukemia compared to those without and between the subtypes of leukemia. Patients with 
leukemia were older, with a m an age difference of about a decade, with older age being an 
already known adverse prognostic factor in AML.13 We observed differences in type of ACS 
presentation in patients with leukemia, with STEMI occurring less commonly. This may be 
due to greater prevalence of type 2 AMIs secondary to supply / demand mismatch in this 
cohort,14 related to their disease-specific comorbidities (anemia, sepsis, dehydration, drug 
toxicity, etc.). Patients with leukemia also had significantly higher prevalence of 
thrombocytopenia (>10% prevalence in all types of leukemia compared to 3% in patients 
without leukemia) with the highest rates (one-quarter) in those with AML. Thrombocytopenia 
may act as deterrent to undertaking coronary angiography and subsequent revascularization in 
patients with AMI and leukemia, given concerns regarding risk of periprocedural bleeding and 
ability to tolerate antiplatelet agents following PCI. However, reassuring data from large cancer 
centers in the US suggests that the use of antiplatelets is safe and improves survival in cancer 
patients with MI and thrombocytopenia, although latest data on newer P2Y12 inhibitors is 
lacking.15,16 Recent data also suggests that if transradial vascular access is performed, 
invasive coronary angiography and PCI can be performed safely in cancer patients with chronic 
thrombocytopenia.17 Coagulopathy was more prevalent in patients with leukemia (17.4% vs 
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4.2%), particularly in patients with AML (29%). This may relate to disseminated intravascular 
coagulation (DIC) secondary to sepsis, hepatic injury, hepatic toxicity or due to a specific type 
of AML (acute promyelocytic leukemia (APL)18whose incidence has been reported as 13% of 
new AML cases19. Renal impairment was more common in patients with leukemia, again 
reflecting an older population with more comorbidities. 
Interestingly, when looking at all-cause bleeding, there was a statistically significant 
difference towards increased bleeding in patients with leukemia, but the difference was only 
0.3%. This may be confounded by the use of less aggressive antithrombotic regimes in this 
patient group, although the NIS does not capture pharmacological therapy. 
We have observed significant differences in the prognosis associated with different 
types of leukemia following admission with AMI. Patients with AML had the worst outcomes, 
with an independent 3-fold increase in MACCE and a 4-fold increase in mortality. AML 
patients also were least likely to undergo invasive management, with less than one third 
undergoing diagnostic coronary angiography and only 20% treated with PCI. This may relate 
to the higher risk profile of these patients, particularly given their elevated bleeding risk, but 
may also relate to the fact that these patients have been excluded from all major trials that have 
shown benefit of invasive strategies in the treatment of ACS. Further data is needed to assess 
whether invasive management might decrease mortality in patients with leukemia presenting 
with an AMI, particularly in AML. Patients with CML had the highest risk of bleeding 
complications (1.20[1.05, 1.37; p<0.007]), which may also be confounded by the age given 
patients with CML have a higher average age compared to patients without leukemia (74 vs 68 
years old). With the advent of tyrosine kinase inhibitors (TKI), the therapeutic options for CML 
patients have expanded significantly.20 Dasatinib, a widely used TKI in CML, has been 
reported to cause increase in risk of bleeding,21 through a mechanism proposed to be mediated 
by platelet dysfunction22.  Part of this increased risk of bleeding in our study could be related 
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to combined treatment of antiplatelet and anticoagulants used for the management of AMI and 
concomitant use of some TKI (imatinib and dasatinib)22 for CML. The risk versus benefit of 
continuing TKI treatment while starting antithrombotic agents in the AMI setting should be 
carefully assessed and individualized in these patients. 
ALL was relatively rare in this cohort (n=379), only accounting for 1.7% of leukemia 
cases, hence the data around outcomes and treatment in ALL is limited. Once the differences 
in the clinical characteristics were adjusted for these patients were found to have a 70% 
increased risk of in-hospital mortality. The most common subtype of leukemia in our study 
was CLL, in keeping with it being the most prevalent leukemia in adults in the western 
hemisphere.23 The majority of CLL patients are diagnosed incidentally and generally have an 
indolent course initially.24 Patients with CLL were on average a decade older than patients 
without leukemia and had a modest increase in the risk of in-hospital mortality (18%).
When managing high-risk groups such as those with leukemia, clinicians need to 
consider both the ischemic and bleeding risks associated with AMI and leukemia, respectively. 
25 Decisions around the treatment of AMI should be made by an interdisciplinary team that 
includes oncology and cardiology as well as other consultative services to balance the risks 
versus the benefits. A cautious approach that includes adoption of careful bleeding avoidance 
strategies should be instituted rather than automatic deferment of the invasive strategies in 
patients presenting with AMI. The use of micro-puncture techniques for vascular access, radial 
access, reduced dosing of anticoagulants in patients with platelet counts <30,000mm3, 
introduction of thinner strut and polymer free platforms and the use of intravascular imaging 
(intravascular ultrasound and Optical Coherence Tomography) to optimize PCI results are 
some of the strategies that  have  enabled the interventional cardio-oncology programs to have 
acceptable rates of complications in this challenging group of patients.26 
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Limitations
First, the NIS is an administrative dataset that is susceptible to coding inaccuracies. 
Although the identification of ACS and leukemia diagnoses as well as other comorbidities was 
based on the use of administrative codes, ICD-9 codes have been previously validated for the 
purposes of cardiovascular research.27 Secondly, since the NIS dataset does not capture 
pharmacotherapy, we were unable to determine differences in the prescription of 
antithrombotic therapy between the study groups. Similarly, NIS does not capture lab values, 
hence the platelet counts, and the degree or type of coagulopathy was unknown. Nevertheless, 
we have adjusted for the presence of thrombocytopenia and coagulopathy in our analysis. 
Additionally, the reduced rates of PCI in those with leukemia may be explained by lack of 
obstructive coronary artery disease in those with a Type 2 AMI. Third, the NIS database does 
not capture the cause of mortality and, therefore, we were unable to determine how much of 
the observed mortality is attributable to cardiovascular causes. Finally, classifications 
regarding the severity and duration of each subtype of leukemia was not possible given 
limitations of ICD-9 codes.
Conclusion
A concomitant leukemia diagnosis in patients presenting with AMI is associated with 
an overall increase in MACCE and mortality, which further differs according to the subtype of 
leukemia. Patients with leukemia are generally older, have more comorbidities, and have 
higher prevalence of coagulopathies and thrombocytopenia, which may deter cardiologists 
from pursuing invasive therapies and may limit the use of antithrombotic agents. Still for the 
most part, we have observed that the in-hospital bleeding risk is low, except in CML. AML has 
the highest risk of mortality with the lowest receipt of invasive strategies / revascularization. 
Clinical management of this complex group of patients should involve a multi-disciplinary 
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team including oncologists and cardiologists. To help improve the care of leukemia patients, 
further studies are needed in order to better assess the risk versus benefit of more aggressive 
management of AMI.
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Figures and Legends:
Figure 1. Rate of revascularization according to subtype of leukemia
Caption: CA: Coronary angiography; PCI: Percutaneous coronary intervention; CABG: 
Coronary artery bypass grafting
Figure 2. Crude rates of adverse events in study groups
Figure 3. Odds ratios and 95% confidence intervals (CI) of adverse events according to 
subtype of leukemia
Caption: MACCE: major adverse cardiovascular and cerebrovascular events: composite
of mortality, stroke and cardiac complications; *non-significant; † p≤0.01; ‡ p≤0.001; *reference group; § non-
significant; † p≤0.01; ‡ p≤0.001
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Table 1. Patient characteristics of study groups
Variable/Group (%) No Leukemia(99.7)
Leukemia
(0.3) Total p-value
Number of weighted discharges 6729184 21694 6750878 <0.001
Age (years), median (IQR) 68(57,79) 77(69,84) 68(57,79) <0.001
Males, % 60.2 65.2 60.2 <0.001
Ethnicity, % <0.001
White 77.1 87.8 77.1
Black 9.7 5.2 9.7
Hispanic 7.4 3.8 7.3
Asian/Pacific Islander 2.2 0.9 2.2
Native American 0.5 0.2 0.5
Other 3.1 2.1 3.1
STEMI, % 35.1 24.8 35.1
Elective Admission, % 7.1 6.7 7.1 <0.001
Weekend admission, % 25.9 25.2 25.9 <0.001
Primary expected payer, % <0.001
Medicare 57.3 80.5 57.4
Medicaid 5.9 1.4 5.9
Private Insurance 27.7 15.0 27.7
Self-pay 5.8 1.1 5.7
No charge 0.6 0.1 0.6
other 2.7 1.9 2.7
Median Household Income 
(percentile), % <0.001
0-25th 28.6 23.5 28.5
26-50th 27.4 28.2 27.4
51-75th 23.7 24.6 23.7
76-100th 20.4 23.7 20.4
Comorbidities, % 
Dyslipidemia 54.2 46.0 54.2 <0.001
Thrombocytopenia 3.1 14.0 3.1 <0.001
Smoking 34.0 21.9 34.0 <0.001
Previous AMI 10.2 10.4 10.2 <0.001
History of IHD 76.7 72.0 76.7 <0.001
Previous PCI 11.4 12.3 11.4 <0.001
Previous CABG 7.5 10.2 7.5 <0.001
Previous CVA 3.8 4.3 3.8 <0.001
Family history of CAD 7.8 3.8 7.8 <0.001
AIDS 0.1 0.0 0.1 <0.001
Alcohol abuse 2.8 1.2 2.8 <0.001
Deficiency anemias 14.6 25.4 14.6 <0.001
Chronic Blood loss anemia 1.1 1.1 1.1 <0.001
RA/collagen vascular
diseases 2.1 2.3 2.1 <0.001
Congestive heart failure 0.9 1.5 0.9 <0.001
Chronic pulmonary disease 20.6 23.2 20.6 <0.001
Coagulopathy 4.2 17.4 4.3 <0.001
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Variable/Group (%) No Leukemia(99.7)
Leukemia
(0.3) Total p-value
Depression 6.3 6.6 6.3 <0.001
Diabetes 28.0 27.1 28.0 <0.001
Diabetes with complications 6.0 5.7 6.0 <0.001
Drug abuse 2.0 0.6 2.0 <0.001
Hypertension 66.3 61.9 66.3 0.287
Hypothyroidism 9.6 11.6 9.6 <0.001
Liver disease 1.2 1.0 1.2 <0.001
Lymphomas 0.5 2.5 0.5 <0.001
Fluid and electrolyte 
disturbances 19.0 23.6 19.1 <0.001
Metastatic cancer 0.9 0.8 0.9 <0.001
Other neurological disorders 5.8 5.6 5.8 <0.001
Obesity 11.6 6.1 11.6 <0.001
Paralysis 1.6 1.3 1.6 <0.001
Peripheral vascular disease 10.8 11.2 10.8 <0.001
Psychoses 2.0 1.5 2.0 <0.001
Pulmonary circulation disorder 0.1 0.2 0.1 <0.001
Renal failure (chronic) 16.4 22.8 16.4 <0.001
Solid tumor without metastases 1.4 2.7 1.4 <0.001
Peptic ulcer disease 0.0 0.1 0.0 0.002
Valvular heart disease 0.3 0.5 0.3 <0.001
Weight loss 2.1 3.0 2.1 <0.001
Hospital bed size, % <0.001
Small 10.4 11.1 10.4
Medium 24.3 23.6 24.3
Large 65.3 65.3 65.3
Hospital Region, % <0.001
Northeast 19.5 22.9 19.5
Midwest 23.3 24.7 23.3
South 39.9 35.2 39.9
West 17.3 17.2 17.3
Location/ Teaching status, % <0.001
Rural 10.5 11.9 10.5
Urban non-teaching 41.9 39.9 41.8
Urban- teaching 47.6 48.2 47.6
AMI: acute myocardial infarction; CABG: coronary artery bypass graft; CAD: coronary artery disease; CVA: 
cerebrovascular accident (stroke or transient ischemic attack); IHD: ischemic heart disease; IQR: interquartile 
range; STEMI: ST-elevation myocardial infarction PCI: percutaneous coronary intervention; 
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Table 2. In-hospital management strategies and clinical outcomes of study groups
CABG: coronary artery bypass grafting; MACCE: major adverse cardiovascular and cerebrovascular 
events: composite of mortality, stroke and cardiac complications; PCI: percutaneous coronary 
intervention






MACCE, % 7.8 11.8 7.8 <0.001
Cardiac complications, % 0.7 0.5 0.7 <0.001
Stroke, % 1.7 1.4 1.7 <0.001
All-cause mortality, % 5.8 10.3 5.8 <0.001
All-cause bleeding, % 5.3 5.6 5.3 <0.001
Use of assist device or 
IABP, % 4.9 3.3 4.9 <0.001
Shock, % 4.9 4.6 4.9 <0.001
Receipt of coronary 
angiography, % 64.5 48.5 64.5 <0.001
Receipt of PCI, % 42.9 28.2 42.9 <0.001
Receipt of CABG, % 8.9 6.9 8.9 <0.001
Length of stay (days), 
median (IQR) 3(2,6) 4(2,7) 3(2,6) <0.001
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Table 3. In-hospital management strategies and clinical outcomes according to leukemia subtype
Variable/Outcome









MACCE, % 21.1 11.0 8.5 10.7 <0.001
Cardiac complications, 
% 0.2 1.0 0.0 0.4 <0.001
Stroke, % 0.9 2.0 1.1 1.4
All-cause mortality, % 20.2 8.4 7.3 9.3 <0.001
All-cause bleeding, % 4.4 7.2 5.1 5.4 <0.001
Use of assist device or 
IABP, % 1.9 2.7 3.7 3.6 <0.001
Shock, % 6.8 4.4 5.2 4.3 <0.001
Receipt of coronary 
angiography, % 33.4 51.6 57.9 49.8 <0.001
Receipt of PCI, % 20.2 28.5 32.6 29.3 <0.001
Receipt of CABG, % 3.2 6.5 6.2 7.5 <0.001
Length of stay (days), 
median (IQR) 4(2,7) 4(2,7) 4(2,8) 4(2,7) 0.760










CABG: coronary artery bypass grafting; MACCE: major adverse cardiovascular and cerebrovascular events: composite
of mortality, stroke and cardiac complications; PCI: percutaneous coronary intervention
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Figure 1. Rate of revascularization according to subtype of leukemia 
Caption: CA: Coronary angiography; PCI: Percutaneous coronary intervention; CABG: Coronary artery 
bypass grafting 
104x64mm (300 x 300 DPI) 
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Figure 2. Crude rates of adverse events in study groups 
110x74mm (300 x 300 DPI) 
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Figure 3. Odds ratios and 95% confidence intervals (CI) of adverse events according to subtype of leukemia 
Caption: MACCE: major adverse cardiovascular and cerebrovascular events: composite 
of mortality, stroke and cardiac complications; *non-significant; † p≤0.01; ‡ p≤0.001; *reference group; § 
non-significant; † p≤0.01; ‡ p≤0.001 
162x97mm (300 x 300 DPI) 
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Supplementary Figure 1. Flow diagram of study design
Supplementary Table 1. Search Codes
Variable Source Codes
Diagnoses 
STEMI ICD-9 410.0x, 410.1x, 410.2x, 410.3x, 
410.4x, 410.5x, 410.6x, 410.8x







Smoking Status ICD-9 V15.82, 305.1 
History of IHD ICD-9 414.00-07, 414.2-9
Previous MI ICD-9 412
Previous PCI ICD-9 V45.82 
Previous CABG ICD-9 V45.81 
Family history of CAD ICD-9 V17.3 
Previous CVA (TIA and 
Stroke)
ICD-9 V12.54
Dementia (Presenile, Senile, 
Vascular and Alzheimer’s)
ICD-9 290.10-13, 290.20-21, 290.40-
43, 294.10-11, 331.0
Thrombocytopenia ICD-9 287.5,287.49,
In-hospital procedures and outcomes
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Acute ischemic stroke ICD-9 433.01, 433.11, 433.21, 433.31, 
433.81433.91, 434.01, 434.11, 
434.91, 435.x, 436
Bleeding ICD-9, CCS 430, 431, 432*, 459.0, 578*, 
784.7, 786.3, 998.11 
(procedure-related bleeding)
Shock during admission ICD-9, CCS 785.51
Use of assist device or IABP ICD-9 37.68, 37.61 
Hemopericardium ICD-9 423.0
Pericardiocentesis ICD-9 37.0






Coronary dissection ICD-9 414.12
ICD-9-CM: International Classification of Diseases, Ninth Edition, Clinical Modification; CCS: Clinical Classification 
Software
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Supplementary Table 2. Patient characteristics according to leukemia subtype
Variable/Group (%) AML CML ALL CLL p-value
Number of weighted discharges 2278 3437 379 15600 <0.001
% within leukemia group 10.5 15.8 1.7 71.9
Age (years), % median (IQR) 74(66,81) 74(65,82) 65(53,72) 79(71,86) <0.001
Males, % 72.8 62.6 73.6 64.4 <0.001
Ethnicity, % <0.001
White 84.0 86.8 78.0 88.8
Black 6.4 6.3 8.1 4.8
Hispanic 6.2 4.3 7.4 3.2
Asian/Pacific Islander 2.9 1.5 0.0 0.5
Native American 0.3 0.3 0.0 0.2
Other 0.2 0.8 6.5 2.5
STEMI, % 25.0 19.1 30.6 25.9 <0.001
Elective Admission, % 7.1 5.9 5.0 6.9 <0.001
Weekend admission, % 23.2 26.3 25.6 25.1 <0.001
Primary expected payer, % <0.001
Medicare 74.9 77.0 60.8 82.6
Medicaid 2.5 1.9 3.5 1.1
Private Insurance 19.0 17.8 31.8 13.4
Self-pay 1.7 1.6 0.0 0.9
No charge 0.4 0.0 0.0 0.1
other 1.5 1.7 3.9 2.0
Median Household Income 
(percentile), % <0.001
0-25th 22.0 25.6 19.7 23.3
26-50th 32.8 24.6 27.8 28.4
51-75th 22.5 25.9 19.7 24.8
76-100th 22.8 23.8 32.8 23.5
Comorbidities, % 
Dyslipidemia 45.8 47.7 47.9 45.7 <0.001
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Variable/Group (%) AML CML ALL CLL p-value
Thrombocytopenia 25.1 12.2 10.6 12.8 <0.001
Smoking 23.4 22.7 19.5 21.5 <0.001
Previous AMI 9.8 12.0 10.2 10.0 <0.001
History of IHD 65.4 76.9 71.6 71.9 <0.001
Previous PCI 10.7 19.0 18.8 10.9 <0.001
Previous CABG 11.9 11.5 8.7 9.8 <0.001
Previous CVA 2.4 5.5 5.1 4.3 <0.001
Family history of CAD 2.3 3.5 3.8 4.0 <0.001
Alcohol abuse 1.7 0.8 1.2 1.2 <0.001
Deficiency anemias 27.1 31.5 17.9 24.0 <0.001
Chronic Blood loss anemia 1.0 1.5 0.0 1.0 <0.001
RA/collagen vascular
diseases 2.8 2.8 5.3 2.1
<0.001
Congestive heart failure 1.0 1.1 6.3 1.5 <0.001
Chronic pulmonary disease 17.9 24.5 16.2 23.8 <0.001
Coagulopathy 29.0 15.8 11.5 16.1 <0.001
Depression 5.9 8.4 7.5 6.3 <0.001
Diabetes 25.8 28.7 33.7 26.8 <0.001
Diabetes with complications 3.8 8.1 10.1 5.3 <0.001
Drug abuse 1.5 0.9 1.0 0.4 <0.001
Hypertension 59.9 64.9 60.3 61.6 <0.001
Hypothyroidism 11.3 12.9 8.9 11.4 <0.001
Liver disease 0.8 1.4 2.4 0.9 <0.001
Lymphomas 2.1 1.0 4.0 2.8 <0.001
Fluid and electrolyte disturbances 24.9 26.2 16.3 23.1 <0.001
Metastatic cancer 0.6 0.5 0.0 0.9 <0.001
Other neurological disorders 4.2 5.2 2.4 6.1 <0.001
Obesity 5.9 8.5 9.6 5.6 <0.001
Paralysis 0.7 1.8 1.4 1.3 <0.001
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Variable/Group (%) AML CML ALL CLL p-value
Peripheral vascular disease 9.7 11.9 10.0 11.3 <0.001
Psychoses 1.8 1.5 2.3 1.4 <0.001
Pulmonary circulation disorder 0.0 0.3 0.0 0.2 <0.001
Renal failure (chronic) 19.9 30.4 15.8 21.8 <0.001
Solid tumor without metastases 2.3 2.7 1.3 2.8 <0.001
Peptic ulcer disease 0.0 0.3 0.0 0.0 <0.001
Valvular heart disease 0.2 0.3 0.0 0.5 <0.001
Weight loss 3.4 3.8 7.6 2.7 <0.001
Hospital bed size, % <0.001
Small 10.5 11.0 8.6 11.2
Medium 23.6 24.3 23.2 23.4
Large 65.8 64.7 68.2 65.4
Hospital Region, % <0.001
Northeast 20.8 23.2 25.2 23.0
Midwest 28.4 22.0 14.0 25.1
South 32.7 37.5 45.0 34.9
West 18.0 17.2 15.8 17.0
Location/ Teaching status, % <0.001
Rural 11.5 9.2 8.7 12.6
Urban non-teaching 34.5 41.9 36.1 40.4
Urban- teaching 53.9 48.9 55.2 47.0
AMI: acute myocardial infarction; CABG: coronary artery bypass graft; CAD: coronary artery disease; CVA: cerebrovascular accident 
(stroke or transient ischemic attack); IHD: ischemic heart disease; IQR: interquartile range; STEMI: ST-elevation myocardial infarction 
PCI: percutaneous coronary intervention; 
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Supplementary Table 3. Adjusted odds ratios 95% confidence intervals of in-hospital adverse outcomes.





















MACCE 1.26[1.20,1.31] <0.001 2.81[2.51,3.13] <0.001 1.34[1.19,1.50] <0.001 1.32[0.90,1.94] 0.155 1.06[0.99,1.11] 0.055
Mortality 1.43[1.37,1.50] <0.001 3.75[3.34,4.22] <0.001 1.34[1.18,1.53] <0.001 1.73[1.14,2.63] 0.01 1.18[1.12,1.26] <0.001
Stroke 0.71[0.64,0.80] <0.001 0.47[0.30,0.73] 0.001 1.04[0.81,1.33] 0.768 0.78[0.31,1.99] 0.609 0.68[0.59,0.78] <0.001
Bleeding 1.00[0.94,0.92] <0.001 0.59[0.48,0.72] <0.001 1.20[1.05,1.37] 0.007 0.75[0.47,1.20] 0.747 0.84[0.79,0.91] <0.001
MACCE: major adverse cardiovascular and ce ebrovascular events: composite of mortality, stroke and cardiac complications
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